L. Rhoda Molife

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Thomas Powles, Elizabeth R. Plimack, Denis Soulières et al. · The Lancet Oncology · 2020 · 745 citations

Medicine, Oncology, Pharmacology +13

Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

Gerhardt Attard, Alison Reid, Roger A’Hern et al. · Journal of Clinical Oncology · 2009 · 603 citations · Full text

Medicine, Oncology, Pharmacology +17

Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

Alison Reid, Gerhardt Attard, Daniel C. Danila et al. · Journal of Clinical Oncology · 2010 · 394 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

L. Rhoda Molife, Yan Li, Joanna Vitfell-Rasmussen et al. · Journal of Hematology & Oncology · 2014 · 190 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

L. Rhoda Molife, Gerhardt Attard, Peter C.C. Fong et al. · Annals of Oncology · 2009 · 184 citations

Medicine, Oncology, Pharmacology +17